

Health Protection scorecard - October 2018

	Significantly worse than England
	Not significantly different to England
	Significantly better than England
	Significance not tested
	- No sub-regional data available
	Above national goal
	Close to national goal
	Below national goal

	Data updated since previous scorecard?	Indicator	Measure	Period	County Durham		North East	England	Recent trend
					No.	Measure			
Screening	N	2.19 - Cancer diagnosed at early stage (experimental statistics)	%	2016	1,133	49.6%	51.2%	52.6%	
	N	2.20i - Cancer screening coverage - breast cancer	%	2017	49,518	78.6%	77.1%	75.4%	
	N	2.20ii - Cancer screening coverage - cervical cancer	%	2017	99,254	76.4%	74.7%	72.0%	
	N	2.20iii - Cancer screening coverage - bowel cancer	%	2017	52,473	61.0%	60.0%	58.8%	
	N	2.20iv - Abdominal Aortic Aneurysm Screening - Coverage	%	2016/17	2,503	79.6%	79.8%	80.9%	
	N	2.20v – Diabetic eye screening - uptake (%)	%	2016/17	-	-	84.6%	82.2%	
	N	2.20vii - Infectious Diseases in Pregnancy Screening – HIV Coverage (%)	%	2016/17	-	-	98.7%	99.5%	
	N	2.20viii - Infectious Diseases in Pregnancy Screening – Syphilis Coverage (%)	%	2015	-	-	96.3%	98.2%	
	N	2.20ix - Infectious Diseases in Pregnancy Screening – Hepatitis B Coverage (%)	%	2015	-	-	96.9%	98.1%	
	N	2.20x - Sickle Cell and Thalassaemia Screening – Coverage (%)	%	2016/17	-	-	99.0%	99.3%	
	N	2.20xi - Newborn Blood Spot Screening – Coverage (%)	%	2016/17	-	-	98.7	96.5	
	N	2.20xii Newborn Hearing Screening – Coverage (%)	%	2016/17	-	-	99.0%	98.4%	
	N	2.20xiii - Newborn and Infant Physical Examination Screening – Coverage (%)	%	2016/17	-	-	89.2%	93.5%	

	Data updated since previous scorecard?	Indicator	Measure	Period	County Durham		North East	England	Recent trend	
					No.	Measure				
Imms and Vaccs		12 months								
	N	3.03i - Population vaccination coverage - Hepatitis B (1 year old)	%	2017/18	-	-	-	-		
	Y	3.03iii - Population vaccination coverage - Dtap / IPV / Hib (1 year old) <90% 90% to 95% ≥95%	%	2017/18	5,293	98.0%	95.5%	93.1%		
	N	3.03iv - Population vaccination coverage - MenC **From 1st July 2016 the dose of MenC offered at 3 months is to be discontinued and so the 1 year evaluation 3.03iv indicator will become obsolete within the next two years (data for 2016/17 will be the last collection) ** <90% 90% to 95% ≥95%	%	2015/16	5,399	98.7%	97.8%	*		
	Y	3.03v - Population vaccination coverage - PCV (1 year old) <90% 90% to 95% ≥95%	%	2017/18	5,300	98.1%	95.7%	93.3%		
		24 months								
	Y	3.03i - Population vaccination coverage - Hepatitis B (2 years old)	%	2016/17	0	0	-	-		
	Y	3.03iii - Population vaccination coverage - Dtap / IPV / Hib (2 years old) <90% 90% to 95% ≥95%	%	2017/18	5,445	98.5%	97.2%	95.1%		
	Y	3.03vi - Population vaccination coverage - Hib / MenC booster (2 years old) <90% 90% to 95% ≥95%	%	2017/18	5,359	96.9%	95.0%	91.2%		
	Y	3.03vii - Population vaccination coverage - PCV booster (2 years old) <90% 90% to 95% ≥95%	%	2017/18	5,363	97.0%	95.0%	91.0%		
	Y	3.03viii - Population vaccination coverage - MMR for one dose (2 years old) <90% 90% to 95% ≥95%	%	2017/18	5,357	96.9%	94.5%	91.2%		
		2-3 years								
	Y	3.03xviii - Population vaccination coverage - Flu (2-3 years old) <40% 40% to 65% >65%	%	2017/18	5,135	45.3%	43.9	43.5%	No trend	
		5 years								
	Y	3.03ix - Population vaccination coverage - MMR for one dose (5 years old) <90% 90% to 95% ≥95%	%	2017/18	5,822	98.1%	97.2%	94.9%		
	Y	3.03vi - Population vaccination coverage - Hib / Men C booster (5 years old) <90% 90% to 95% ≥95%	%	2017/18	5,768	97.2%	95.1%	92.4%		
	Y	3.03x - Population vaccination coverage - MMR for two doses (5 years old) <90% 90% to 95% ≥95%	%	2017/18	5,671	95.5%	91.9%	87.2%		
		Other Children and young people								
	N	3.03xii - Population vaccination coverage - HPV vaccination coverage for one dose (females 12-13 years old) <80% 80% to 90% ≥90%	%	2016/17	2,311	90.7%	89.8%	87.2%		
	N	3.03xvi - Population vaccination coverage - HPV vaccination coverage for two doses (females 13-14 years old) <80% 80% to 90% >90%	%	2016/17	2,127	87.4%	84.2%	83.1%		
		Other								
	N	Persons entering substance misuse treatment - Percentage of eligible persons completing a course of hepatitis B vacc			2016/17	32	3.6%	6.0%	8.1%	
	Y	3.03xv - Population vaccination coverage - Flu (at risk individuals) <55% ≥55%	%	2017/18	34,518	50.2%	49.9%	48.9%		
	Y	3.03xiv - Population vaccination coverage - Flu (aged 65+) <75% ≥75%	%	2017/18	79,588	75.2%	73.9%	72.6%		
Y	3.03xiii - Population vaccination coverage - PPV (aged 65+) <65% 65% to 75% ≥75%	%	2017/18	37,998	70.2%	71.0%	69.5%			
N	3.03xvii - Population vaccination coverage - Shingles vaccination coverage (70 years old) <50% 50% to 60% ≥60%	%	2016/17	3036	53.3%	51.5%	48.3%			

	Data updated since previous scorecard?	Indicator	Measure	Period	County Durham		North East	England	Recent trend
					No.	Measure			
Sexual health	N	3.02 - Chlamydia detection rate / 100,000 aged 15-24	R/100,000	2017	1085	1620	2033	1882	
			<1,900 1,900 to 2,300 ≥2,300						
	N	All new STI diagnoses (exc Chlamydia aged <25) / 100,000	R/100,000	2017	1893	569	644	794	
	N	Gonorrhoea diagnosis rate per 100,000 population	R/100,000	2017	273	52.3	67.4	78.8	
N	Syphilis diagnoses rate per 100,000 population	R/100,000	2017	20	3.8	7.7	12.5		
Y	3.04 - HIV late diagnosis (%)	R/100,000	2015-17	21	33.3%	40.3	41.1		
									≥50% 25% to 50% <25%
Infectious diseases	N	Legionnaire's disease confirmed incidence rate / 100,000	R/100,000	2015	0	0	0.95	0.67	No trend
	Y	Typhoid and paratyphoid confirmed incidence rate / 100,000	R/100,000	2017	0	0	0.19	0.53	
	Y	3.05ii - TB incidence (three year average)	R/100,000	2015-17	26	1.7	4.5	9.9	
	Y	3.05i - Treatment completion for TB (%)	%	2016	6	85.7	81.3	84.4	
	Y	Measles (reported cases confirmed, Year to date)	R/100,000	Q2 2018	0	0	0	-	
	Y	Measles new diagnosis rate	R/100,000	2016	0	0	0.1	1	
	Y	<i>Mumps (confirmed cases, quarterly number and annualised rates)</i>	R/100,000	Q2 2018	3	2.3	1.2	-	
	Y	<i>Mumps (confirmed cases, quarterly number and annualised rates)</i>	R/100,000	Q2 2018	4	3.1	1.7	-	
	N	<i>Rubella (confirmed cases, year to date)</i>	R/100,000	Q4 2017/18	1	0.2	0	-	No trend
	Y	<i>Meningococcal Infection (confirmed cases, quarterly number and annualised rates)</i>	R/100,000	Q2 2018	1	0.8	1.4	-	
	Y	<i>Scarlet Fever (all notifications)</i>	R/100,000	Q2 2018	111	85	97.5	-	
	N	<i>Haemophilus Influenzae Type B (HiB)</i>	R/100,000	Q4 2017/18	0	0	0	-	
	Y	Non-typhoidal Salmonella (incidence)	R/100,000	2017	92	17.6	16.6	15.7	
	Y	<i>Quarterly Salmonella Enteritidis (incidence)</i>	R/100,000	Q2 2018	2	1.5	2.4	-	
	Y	<i>Quarterly Salmonella Typhimurium (incidence)</i>	R/100,000	Q2 2018	5	3.8	2.4	-	
	Y	<i>Quarterly Salmonella other (incidence)</i>	R/100,000	Q2 2018	4	3.1	4.2	-	
	Y	Campylobacter (incidence)	R/100,000	2017	689	132	123	97	
	Y	<i>Quarterly Campylobacter (incidence)</i>	R/100,000	Q2 2018	190	145.6	155.5	-	
	Y	Cryptosporidium (incidence)	R/100,000	2017	75	14.4	10.4	7.3	
	Y	<i>Quarterly Cryptosporidium (incidence)</i>	R/100,000	Q2 2018	16	12.3	10.3	-	
Y	Giardia (incidence)	R/100,000	2017	35	6.7	11.9	8.5		
Y	<i>Quarterly Giardia (incidence)</i>	R/100,000	Q2 2018	4	3.1	12	-		
Y	STEC serogroup O157 (incidence)	R/100,000	2016	12	2.3	1.5	1.2		